Anpario plc (AIM:ANP)

London · Delayed Price · Currency is GBP · Price in GBX

512.00

+10.00 (1.99%)

Apr 28, 2026, 4:29 PM GMT

32.99% (1Y)

Market Cap	103.39M
Revenue (ttm)	47.18M
Net Income (ttm)	6.75M
Shares Out	20.60M
EPS (ttm)	0.38
PE Ratio	13.23
Forward PE	11.97
Dividend	0.13 (2.62%)
Ex-Dividend Date	Jul 9, 2026

Volume	27,969
Average Volume	60,252
Open	494.16
Previous Close	502.00
Day's Range	494.16 - 512.00
52-Week Range	370.00 - 580.00
Beta	0.99
RSI	56.43
Earnings Date	Mar 31, 2026

About Anpario

Anpario plc, together with its subsidiaries, manufactures and distributes natural animal feed additives for animal health, nutrition, and biosecurity. Its health and performance category offers various products that support and maintain animal gut health, including phytogenic and acid based eubiotics, and omega fatty acids under the Orego-Stim, Optomega, pHorce, Salkil, and Genex brands; and feed quality category provides products, such as enzymes, antioxidants, pellet binders, mould inhibitors, and acid based eubiotics under the pHorce, Feedzy... [Read more]

Industry Packaged Foods

Sector Consumer Staples

Founded 1996

Employees 162

Stock Exchange London Stock Exchange AIM

Ticker Symbol ANP

Full Company Profile

Financial Performance

In 2025, Anpario's revenue was 47.18 million, an increase of 23.51% compared to the previous year's 38.20 million. Earnings were 6.75 million, an increase of 64.20%.

Financial Statements

News

Half Year 2025 Anpario PLC Earnings Call Transcript

6 months ago - GuruFocus

Full Year 2024 Anpario PLC Earnings Presentation Transcript

6 months ago - GuruFocus

Anpario Earnings Call Transcript: H1 2025

Revenue rose 34% year-over-year, with strong growth across most regions and a significant contribution from the Bio-Vet acquisition. Gross margin and profitability improved, cash reserves increased, and the outlook remains positive despite ongoing trade and credit risks.

8 months ago - Transcripts

Anpario Earnings Call Transcript: H2 2024

Revenue and profit rebounded strongly with 23% top-line growth and a 57% rise in adjusted EBITDA, driven by broad-based segment recovery and the Bio-Vet acquisition. Gross margins improved, cash remains strong, and the outlook is positive with continued focus on growth and resilience.

1 year ago - Transcripts

Anpario Earnings Call Transcript: H1 2024

Gross margin recovery, strong cash generation, and global diversification underpin optimism for high single-digit sales growth. Ongoing product innovation, M&A, and operational leverage are expected to drive future profit expansion despite regulatory and logistics risks.

1 year ago - Transcripts